RNA icon

Avidity Biosciences

32.65 USD
+0.49
1.52%
At close Apr 30, 4:00 PM EDT
After hours
32.65
+0.00
0.00%
1 day
1.52%
5 days
6.94%
1 month
10.60%
3 months
0.06%
6 months
-24.46%
Year to date
4.71%
1 year
35.31%
5 years
14.56%
10 years
14.56%
 

About: Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.

Employees: 391

0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 8 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

13% more repeat investments, than reductions

Existing positions increased: 86 | Existing positions reduced: 76

0% more ownership

Funds ownership: 106.96% [Q3] → 106.96% (+0%) [Q4]

4% less first-time investments, than exits

New positions opened: 49 | Existing positions closed: 51

6% less call options, than puts

Call options by funds: $19.5M | Put options by funds: $20.9M

3% less funds holding

Funds holding: 242 [Q3] → 234 (-8) [Q4]

20% less funds holding in top 10

Funds holding in top 10: 10 [Q3] → 8 (-2) [Q4]

35% less capital invested

Capital invested by funds: $5.75B [Q3] → $3.71B (-$2.04B) [Q4]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$48
47%
upside
Avg. target
$64
97%
upside
High target
$72
121%
upside

8 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Joseph Stringer
26% 1-year accuracy
29 / 113 met price target
84%upside
$60
Buy
Reiterated
9 Apr 2025
HC Wainwright & Co.
Andrew Fein
32% 1-year accuracy
113 / 354 met price target
121%upside
$72
Buy
Reiterated
18 Mar 2025
Chardan Capital
Keay Nakae
18% 1-year accuracy
13 / 73 met price target
99%upside
$65
Buy
Maintained
17 Mar 2025
Citigroup
Geoff Meacham
45% 1-year accuracy
15 / 33 met price target
114%upside
$70
Buy
Initiated
13 Mar 2025
BMO Capital
Kostas Biliouris
6% 1-year accuracy
1 / 17 met price target
121%upside
$72
Outperform
Initiated
12 Mar 2025

Financial journalist opinion

Based on 4 articles about RNA published over the past 30 days

Neutral
PRNewsWire
1 week ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 263,000 shares of its common stock and 131,450 restricted stock units ("RSUs") to thirty-three (33) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
PRNewsWire
3 weeks ago
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan  SAN DIEGO , April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation (ODD) to delpacibart etedesiran (del-desiran) for the treatment of myotonic dystrophy type 1 (DM1), an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies. Del-desiran is the first investigational treatment for DM1 to receive Orphan Drug designation in Japan.
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1
Positive
Zacks Investment Research
3 weeks ago
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock?
Neutral
PRNewsWire
4 weeks ago
Avidity Biosciences to Participate in Upcoming Investor Conference
SAN DIEGO , April 1, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:00 p.m. ET Live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations.
Avidity Biosciences to Participate in Upcoming Investor Conference
Neutral
PRNewsWire
1 month ago
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initiation anticipated in Q2 2025 Plan to present topline data from FORTITUDE dose escalation cohorts in Q2 2025 On track to be first globally approved drug for FSHD SAN DIEGO , March 31, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the completion of enrollment in the biomarker cohort in the Phase 1/2 FORTITUDE™ clinical trial of delpacibart braxlosiran (del-brax) in people living with facioscapulohumeral muscular dystrophy (FSHD). A total of 51 participants were enrolled in the FORTITUDE biomarker cohort.
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy
Neutral
PRNewsWire
1 month ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , March 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on March 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 101,200 shares of its common stock and 50,900 restricted stock units ("RSUs") to sixteen (16) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4).
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
PRNewsWire
1 month ago
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
On track for year end 2025 BLA submission for accelerated approval of 5 mg/kg every six weeks of del-zota in DMD44 Consistent favorable safety and tolerability across del-zota dose cohorts  Plan to present functional data in fourth quarter of 2025 Investor and analyst webcast event today at 8:00 a.m. ET SAN DIEGO , March 17, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced positive del-zota topline data from the Phase 1/2 EXPLORE44® trial in people living with Duchenne muscular dystrophy amenable to exon 44 skipping (DMD44) demonstrating consistent, statistically significant improvements in dystrophin, exon skipping and creatine kinase as well as favorable safety and tolerability across the dose cohorts.
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial
Neutral
PRNewsWire
1 month ago
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Aravindhan Veerapandiyan, MD, Associate Professor of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital and EXPLORE44 ® trial investigator, will present topline del-zota data from Phase 1/2 EXPLORE44 trial at 2025 MDA Clinical & Scientific Conference in Dallas, Texas Avidity to host investor and analyst webcast event March 17, 2025, at 8:00 a.m. ET Key opinion leaders to participate in Avidity sponsored industry forum event "Advancing RNA Therapeutics", March 17, 2025, at 7:00 a.m.
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Neutral
PRNewsWire
2 months ago
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
SAN DIEGO , Feb. 28, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it is joining the global community of patients, caregivers, families and healthcare providers to build broader awareness of rare diseases, including rare neuromuscular diseases, and the urgent need for more approved treatments for many of these conditions in support of Rare Disease Day®. "Rare Disease Day represents an important opportunity for all of us, including people living with rare diseases, their friends, family and caregivers, and advocacy organizations around the world, to spotlight the many challenges that rare diseases present in daily living," said Sarah Boyce, President and Chief Executive Officer at Avidity.
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases
Negative
Zacks Investment Research
2 months ago
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.84. This compares to loss of $0.79 per share a year ago.
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates
Charts implemented using Lightweight Charts™